FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911655024> ?p ?o ?g. }

• W2911655024 abstract "367 Background: Sorafenib, an oral multikinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC) treatment. Predictive biomarkers of sorafenib are needed due to its frequent adverse effect. Lymphocyte to monocyte ratio (LMR) has been reported as a prognostic or predictive biomarker of chemotherapy in cancer. However, clinical significance of LMR are unclear as predictive biomarker of sorafenib. To investigate the efficacy prediction value of LMR in patients who received sorafenib for recurrent HCC after curative resection. Methods: Clinicopathological data of 59 patients who received sorafenib for recurrent HCC after surgical treatment between 2009 and 2017 were retrospectively analyzed. Sorafenib was administered at a dose of 400mg or 800mg. Survival outcomes were estimated using the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate analyses were performed to evaluate the predictive impact of LMR and other clinicopathological factors for efficacy of sorafenib on overall survival (OS) and progression free survival (PFS). Results: The optimal cutoff value of LMR for response evaluation was 3.1, which resulted in the most appropriate sensitivity of 60.5% and specificity of 71.4%, with the area under the curve (AUC) of 0.641 (95% C.I.: 0.515-0.806). All patients were divided into either a low ( < 3.1) LMR (LLMR) group (n = 27), or a high ( > 3.1) LMR (HLMR) group (n = 32). Patients with HLMR group had significantly increased OS (MST: 20.0M vs 8.0M, P = 0.001) and PFS (MST: 10.2M vs 5.1M, P < 0.001) compared to those with a LLMR group. Multivariate analyses indicated that a HLMR was a significantly independent predictor of superior OS (P = 0.006) and PFS (P < 0.001). Conclusions: LMR in pre-administration of sorafenib was demonstrated to serve as an independent efficacy prediction factor of sorafenib in recurrent HCC patients after curative resection." @default.
• W2911655024 created "2019-02-21" @default.
• W2911655024 creator A5004749761 @default.
• W2911655024 creator A5015142274 @default.
• W2911655024 creator A5038015017 @default.
• W2911655024 creator A5072493618 @default.
• W2911655024 creator A5076342751 @default.
• W2911655024 creator A5078905421 @default.
• W2911655024 creator A5083850308 @default.
• W2911655024 creator A5086522106 @default.
• W2911655024 date "2019-02-01" @default.
• W2911655024 modified "2023-09-24" @default.
• W2911655024 title "The effect of lymphocyte-to-monocyte ratio on efficacy of sorafenib for recurrent hepatocellular carcinoma after curative resection." @default.
• W2911655024 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.367" @default.
• W2911655024 hasPublicationYear "2019" @default.
• W2911655024 type Work @default.
• W2911655024 sameAs 2911655024 @default.
• W2911655024 citedByCount "0" @default.
• W2911655024 crossrefType "journal-article" @default.
• W2911655024 hasAuthorship W2911655024A5004749761 @default.
• W2911655024 hasAuthorship W2911655024A5015142274 @default.
• W2911655024 hasAuthorship W2911655024A5038015017 @default.
• W2911655024 hasAuthorship W2911655024A5072493618 @default.
• W2911655024 hasAuthorship W2911655024A5076342751 @default.
• W2911655024 hasAuthorship W2911655024A5078905421 @default.
• W2911655024 hasAuthorship W2911655024A5083850308 @default.
• W2911655024 hasAuthorship W2911655024A5086522106 @default.
• W2911655024 hasConcept C126322002 @default.
• W2911655024 hasConcept C143998085 @default.
• W2911655024 hasConcept C185592680 @default.
• W2911655024 hasConcept C2778019345 @default.
• W2911655024 hasConcept C2778695046 @default.
• W2911655024 hasConcept C2781197716 @default.
• W2911655024 hasConcept C38180746 @default.
• W2911655024 hasConcept C55493867 @default.
• W2911655024 hasConcept C71924100 @default.
• W2911655024 hasConcept C90924648 @default.
• W2911655024 hasConceptScore W2911655024C126322002 @default.
• W2911655024 hasConceptScore W2911655024C143998085 @default.
• W2911655024 hasConceptScore W2911655024C185592680 @default.
• W2911655024 hasConceptScore W2911655024C2778019345 @default.
• W2911655024 hasConceptScore W2911655024C2778695046 @default.
• W2911655024 hasConceptScore W2911655024C2781197716 @default.
• W2911655024 hasConceptScore W2911655024C38180746 @default.
• W2911655024 hasConceptScore W2911655024C55493867 @default.
• W2911655024 hasConceptScore W2911655024C71924100 @default.
• W2911655024 hasConceptScore W2911655024C90924648 @default.
• W2911655024 hasLocation W29116550241 @default.
• W2911655024 hasOpenAccess W2911655024 @default.
• W2911655024 hasPrimaryLocation W29116550241 @default.
• W2911655024 hasRelatedWork W2272794294 @default.
• W2911655024 hasRelatedWork W2310235470 @default.
• W2911655024 hasRelatedWork W2404869932 @default.
• W2911655024 hasRelatedWork W2800623797 @default.
• W2911655024 hasRelatedWork W2845403393 @default.
• W2911655024 hasRelatedWork W2893576832 @default.
• W2911655024 hasRelatedWork W3013219946 @default.
• W2911655024 hasRelatedWork W3018861914 @default.
• W2911655024 hasRelatedWork W3167709031 @default.
• W2911655024 hasRelatedWork W4237487304 @default.
• W2911655024 isParatext "false" @default.
• W2911655024 isRetracted "false" @default.
• W2911655024 magId "2911655024" @default.
• W2911655024 workType "article" @default.